PCN64 The Cost Effectiveness of Cetuximab Plus Best Supportive Care (BSC) Versus BSC Alone in Last Line for KRAS Wild Type Metastatic Colorectal Cancer Patient Population
Jun 1, 2012, 00:00
10.1016/j.jval.2012.03.1181
https://www.valueinhealthjournal.com/article/S1098-3015(12)01246-6/fulltext
Title :
PCN64 The Cost Effectiveness of Cetuximab Plus Best Supportive Care (BSC) Versus BSC Alone in Last Line for KRAS Wild Type Metastatic Colorectal Cancer Patient Population
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)01246-6&doi=10.1016/j.jval.2012.03.1181
First page :
A219
Section Title :
Cancer
Open access? :
No
Section Order :
699